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SOX2 suppresses CDKN1A to 
sustain growth of lung squamous 
cell carcinoma
Takuya Fukazawa1, Minzhe Guo4,5, Naomasa Ishida1, Tomoki Yamatsuji1, 
Munenori Takaoka1,  Etsuko Yokota1, Minoru Haisa1, Noriko Miyake3, Tomoko Ikeda3, 
Tatsuo Okui6, Nagio Takigawa2, Yutaka Maeda5 & Yoshio Naomoto1
Since the SOX2 amplification was identified in lung squamous cell carcinoma (lung SCC), SOX2 
transcriptional downstream targets have been actively investigated; however, such targets are often 
cell line specific. Here, in order to identify highly consensus SOX2 downstream genes in lung SCC 
cells, we used RNA-seq data from 178 lung SCC specimens (containing tumor and tumor-associated 
cells) and analyzed the correlation between SOX2 and previously-reported SOX2-controlled genes in 
lung SCC. In addition, we used another RNA-seq dataset from 105 non-small cell lung cancer cell lines 
(NSCLC; including 4 lung SCC cell lines) and again analyzed the correlation between SOX2 and the 
reported SOX2-controlled genes in the NSCLC cell lines (no tumor-associated cells). We combined the 
two analyses and identified genes commonly correlated with SOX2 in both datasets. Among the 99 
genes reported as SOX2 downstream and/or correlated genes, we found 4 negatively-correlated (e.g., 
CDKN1A) and 11 positively-correlated genes with SOX2. We used biological studies to demonstrate 
that CDKN1A was suppressed by SOX2 in lung SCC cells. G1 cell cycle arrest induced by SOX2 siRNA was 
rescued by CDKN1A siRNA. These results indicate that the tumorigenic effect of SOX2 in lung SCC cells 
is mediated in part by suppression of CDKN1A.
Lung squamous cell carcinoma (lung SCC) is the second most frequent type of non-small cell lung carcinoma 
(NSCLC) after lung adenocarcinoma (lung AC)1. In contrast to the recent discovery of targeted therapies for 
lung AC, including EGFR mutant or ALK fusions, there is no effective therapy for lung SCC other than chemo-
therapy2–4. In order to understand the molecular pathogenesis that leads to identifying potential therapeutic 
molecular targets for lung SCC, extensive genetic analysis, including next-generation sequencing, have been per-
formed, which has revealed amplification of SOX2, PIK3CA, PDGFRA, BRF2 and FGFR1, deletion of CDKN2A/B, 
PTEN, TP53 and NF1, and mutations of PIK3CA, NRF2, DDR2, PTEN, EPHA2, LKB1 and AKT1 in lung SCC5,6. 
The genomic amplification of SOX2 is seen in 20% of lung SCC7 while increased expression of SOX2 is seen in 
90% of lung SCC8, suggesting that SOX2 mediates a major tumorigenic effect on lung SCC regardless of genetic 
alterations.
SOX2 plays an oncogenic role not only in lung SCC but also in other cancers, including lung AC, ovarian, 
breast, esophageal, gastric, colon and pancreatic cancers9–13. SOX2 is a transcription factor, thus SOX2 down-
stream genes that exert a tumorigenic effect have been actively sought in such different types of cancers (sum-
marized in Table 1). However, due to its relatively recent finding as an oncogene11, consensus SOX2 downstream 
targets that bear a tumorigenic function have not been established yet. In the present study, we utilized gene 
expression data from The Cancer Genome Atlas (TCGA) human lung SCC samples (n = 178)14 and determined 
a correlation in lung SCC between SOX2 and previously-reported SOX2 downstream targets in the multiple 
cancer cell lines. The limitation of using this TCGA lung SCC dataset is that the expression of each gene in the 
dataset is comprised of the combined gene expression profiles of tumor cells and tumor-associated endothelial 
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CDKN1A 
(p21) repress repress repress repress
CDKN1B 
(p27) No change activate repress
CCND1 activate repress
CCND3 activate
CTTNB1 activate activate
MYC activate
WNT1 activate
WNT2 activate
NOTCH1 activate
MAP4K4 repress
PMAIP1 activate repress
TP73 repress
GADD45A repress
BCl2 activate
BCL2L1 activate
BIRC5
TP63 activate
KRT6A activate
EGFR activate
ETV4 activate
FOXA2 repress
HNF4A repress
EOMES repress
SOX17 repress
BMP2 repress
BMP4 repress
CDH1 No change repress repress
TJP1 repress
VIM repress activate
ZEB1 repress activate
SNAI1 activate
SNAI2 activate
TWIST1 activate
PROM1 activate
CD44 activate
ALDH1 activate
CBX5 activate
GATA3 activate
MYCL activate
HOXB7 activate
HOXC4/
HOXC6 activate
RIT1 activate
IGFBP5 activate
NRG1 activate
FGFBP1 activate
HPLH1 repress
PTGIS repress
CASP1 repress
CASP4 repress
CLU repress
TGFBR3 repress
TNFSF10 repress
Table 1.  Previously reported SOX2 downstream genes in different cancer cell.
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cells, fibroblasts and immune cells, which hampers the identification of tumor cell-specific gene-to-gene cor-
relations. Thus, we also utilized another gene expression dataset from non-small cell lung cancer (NSCLC) cell 
lines (n = 105), including 4 lung SCC cell lines15, and assessed the correlation between SOX2 and the reported 
SOX2 downstream targets in the NSCLC cell lines. The limitation of using this NSCLC cell line dataset is that 
it includes not only lung SCC cell lines but also other lung carcinoma cell lines (e.g., lung AD cell lines). Thus, 
after we analyzed the two datasets, we selected genes that were commonly correlated with SOX2 in both datasets, 
which would likely be SOX2-correlated genes specific to lung SCC cells. Among 99 genes identified in previous 
reports as regulated by or correlated with SOX2 in multiple cancer cell lines, the expression of only 15 genes was 
positively or negatively correlated with the expression of SOX2 in both the 178 lung SCC specimens and the 105 
NSCLC cell lines. Among the 15 genes, CDKN1A (also known as p21[Cip1/Waf1]) that induces G1 cell cycle 
arrest was determined by RNA interference and adenovirus-mediated ectopic expression experiments to be a 
negative downstream target of SOX2 in multiple lung SCC cell lines. G1 cell cycle arrest induced by the reduction 
of SOX2 was reinstated by the reduction of CDKN1A in lung SCC cell lines, indicating that CDKN1A is an intrin-
sic SOX2 target influencing tumorigenicity in lung SCC cells. Here, we report that CDKN1A is a highly consensus 
gene target of the oncogenic transcription factor SOX2 in lung SCC cells.
Results
In order to identify highly consensus SOX2 downstream genes in lung SCC cells, we investigated genes previ-
ously reported to be regulated by SOX2 in multiple cancer cell lines. As shown in the Table 1, SOX2 regulates 
cell cycle-related genes positively or negatively. CDKN1A, which induces G1 arrest, is repressed by SOX2 in 
A549 lung carcinoma cells, pancreatic cancer cells13,16 and gastric cancer cells17. CDKN1B, which also induces 
G1 arrest, is repressed by SOX2 in pancreatic cancer cells and gastric cancer cells. CCND1, which accelerates 
cell cycle, is activated by SOX2 in gastric cancer cells and MCF7 breast cancer cells10,17. Overall, SOX2 represses 
cell cycle inhibitors and activates cell cycle accelerators; however, the pattern of gene regulation is not universal 
in different cancer cell types. Additionally, genes comprising the WNT, NOTCH, RAS, TGF/BMP and EMT 
pathways that are involved in cancer progression and metastasis are regulated by SOX2 in multiple cancer cell 
lines9,16,18–20 (summarized in Table 1). In addition to genes identified as regulated by SOX2 in previous reports, 
we hypothesized that the previously reported top 50 genes positively correlated with SOX2 expression in stage I/
II lung SCC11 might be directly regulated by SOX2 in lung SCC cells. In total, we selected 99 genes that might be 
commonly regulated by SOX2 in lung SCC cells (Table 1).
Next, in order to determine which of the possible 99 genes are correlated with SOX2 in lung SCC cells, we 
used a RNA-seq dataset from TCGA14 to determine whether the expression of any of the 99 genes is correlated 
with that of SOX2 in 178 lung SCC specimens. The 178 lung SCC specimens were divided into two groups, 
SOX2-HIGH and SOX2-LOW groups, based on the median level of SOX2 expression in the lung SCC specimens 
(see Materials and Methods for details). Then, we assessed which genes are correlated with SOX2. As shown in 
Fig. 1, 57 genes (e.g., BMP7) were positively correlated with SOX2 while 11 genes (e.g., CDKN1A) were negatively 
correlated with SOX2 in lung SCC, suggesting that these genes might be regulated by SOX2 in lung SCC cells; 
however, it remains unknown whether the gene-to-gene correlation would be intrinsic or extrinsic since the 
TCGA lung SCC data contains gene expression from heterogeneous cell populations, including not only tumor 
cells but also tumor-associated cells. Thus, we used another RNA-seq dataset from 105 non-small cell lung can-
cer (NSCLC) cell lines (including 4 lung SCC cell lines)15 and performed the same analysis (see Materials and 
Methods for details). As shown in Fig. 2, 12 genes (e.g., BMP7) were positively correlated with SOX2 while 8 genes 
(e.g., CDKN1A) were negatively correlated with SOX2 in the NSCLC cells, suggesting that these genes might be 
regulated by SOX2 in lung SCC cells. Although the NSCLC cell lines do not contain tumor-associated cells, the 
gene-to-gene correlations might occur in non-lung SCC cells (e.g., lung AD cells). Thus, we combined the two 
analyses (Figs 1 and 2) and sought to identify most probable gene-to-gene correlation in lung SCC cells. Among 
the 99 genes, BMP7, CHAC1, DHX9, GPX2, MARK1, MSH6, PRKX, RMND5A, SIAH2, TMPRSS4 and USP39 
were positively correlated while BMP2, CDKN1A, SNAI1 and VIM were negatively correlated with SOX2 in both 
datasets, suggesting that these genes are intrinsically regulated by SOX2 in lung SCC cells.
Next, in order to confirm whether the RNA-seq data analyses indeed reflect their correlation at the protein 
level in lung SCC cell lines, we performed western blotting using cell extracts from six lung SCC cell lines and 
determined the protein expression of SOX2 and two G1 cell cycle inhibitors CDKN1A and CDKN1B. We focused 
on these cell cycle genes since SOX2 has been shown by several groups to influence cell proliferation in vitro13,16. 
CDKN1B was repressed by SOX2 in pancreatic cancer cell lines13; however, a negative correlation with SOX2 was 
not observed in our RNA-seq data analyses (Figs 1 and 2). Consistent with our RNA-seq data analyses (Figs 1 and 2), 
lung SCC cell lines (EBC2, LK2 and H520) that had a high expression of SOX2 had no expression of CDKN1A at 
the protein level. Conversely, lung SCC cell lines (EBC1, H226 and SQ5) that had a low expression of SOX2 did 
express CDKN1A (Fig. 3A), indicating that the expression of SOX2 and CDKN1A is inversely related. In addition 
to the expression in the cell lines, we also investigated the expression of SOX2 and CDKN1A in human primary 
lung SCC specimens. As shown in Supplemental Fig. 1, the majority of lung SCC specimens expressing SOX2 did 
not express CDKN1A. As indicated in the RNA-seq data analysis (Figs 1 and 2), any correlation between SOX2 
and CDKN1B in the various lung SCC cell lines was not observed at the protein level (Fig. 3A,C), which suggests 
that SOX2 regulates CDKN1B in a cell-type specific fashion (pancreatic cancer vs. lung SCC). A similar negative 
correlation between SOX2 and VIM that was indicated by the RNA-seq data analyses (Figs 1 and 2) was also 
observed at the protein level in lung SCC cell lines (Supplemental Figure 2A).
Next, in order to determine whether SOX2 indeed functionally regulates the expression of CDKN1A, we 
employed a RNA interference approach using SOX2 siRNA. Knockdown of SOX2 by RNA interference has been 
shown to inhibit cell viability and colony formation of lung SCC cells, again indicating that SOX2 sustains cell 
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proliferation11. We were able to reproduce the effect of SOX2 using two independent siRNAs in multiple lung SCC 
cell lines in vitro and in vivo (Supplemental Figure 3A, 3B and 3C). Then, we investigated using these siRNAs tar-
geting SOX2 to determine whether suppression of SOX2 influences the expression of CDKN1A in lung SCC cells. 
As shown in Fig. 3B,C, CDKN1A but not CDKN1B was induced by the two independent siRNAs targeting SOX2 
in multiple lung SCC cell lines at the mRNA and protein levels, indicating that SOX2 functionally suppresses the 
expression of CDKN1A. TP53 is known to induce CDKN1A21; however, the expression of TP53 was not influ-
enced by SOX2 siRNAs (Fig. 3C), indicating that SOX2 suppresses CDKN1A in lung SCC cells not through TP53. 
Additionally, CDKN1A was induced by SOX2 siRNAs in the presence of cycloheximide (Supplemental Fig. 4), 
suggesting the direct suppression of CDKN1A by SOX2, as has been reported in pancreatic cancer cells13. VIM 
and ZEB1 expression were also induced by these SOX2 siRNAs in lung SCC cell lines (Supplemental Figure 2B, 
Figure 1. SOX2 positively or negatively correlated genes in the human lung squamous cell carcinoma 
(SCC) samples from the TCGA. The Cancer Genome Atlas (TCGA) human lung squamous cell carcinoma 
(SCC) samples (n = 178) were divided into two groups that have high RNA expression of SOX2 (HIGH, n = 89) 
or low expression of SOX2 (LOW, n = 89). Two-tailed Welch’s t-test was used to determine the significance 
of gene expression between the two groups. Genes with significantly higher expression in the HIGH group 
(p < 0.05 and average expression > 1) were considered as SOX2 positively correlated genes, while genes with 
significantly higher expression in the LOW group (p < 0.05 and average expression > 1) were considered as 
SOX2 negatively correlated genes. The expression was measured in RPKM and quantile normalized. PLA2G4B 
was not present in the TCGA SCC dataset. Results represent the mean ± S.E.M. *indicates p < 0.05, **indicates 
p < 0.01, and ***indicates p < 0.001.
www.nature.com/scientificreports/
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2C), indicating that SOX2 functionally suppresses the expression of VIM and ZEB1. The negative correlation 
between SOX2 and ZEB1 was indicated by the bioinformatical analysis using the 105 NSCLC cell lines dataset 
but not the 178 lung SCC specimens dataset (Figs 1 and 2); however the biological analysis indicated that SOX2 
intrinsically regulates ZEB1 in lung SCC cells, suggesting the requirement of validating bioinformatical anal-
ysis by biological experiments. We further confirmed the effect of SOX2 using adenovirus-expressing SOX2. 
Adenovirus-mediated expression of SOX2 significantly suppressed the expression of CDKN1A at the mRNA and 
protein levels (Fig. 3D). These loss-of-function and gain-of-function experiments indicate that SOX2 negatively 
regulates the expression of the G1 cell cycle inhibitor CDKN1A in lung SCC cells.
Figure 2. SOX2 positively or negatively correlated genes in the human non-small cell lung cancer (NSCLC) 
cell lines. Human non-small cell lung cancer (NSCLC) cell lines (n = 105) were separated into two groups that 
have high RNA expression of SOX2 (HIGH, n = 20) or low expression of SOX2 (LOW, n = 85). The expression 
of previously reported SOX2 downstream or correlated genes was assessed as to whether the expression of those 
genes was correlated with that of SOX2. Two-tailed Welch’s t-test was used to determine the significance of gene 
expression between the two groups. Genes with significantly higher expression in the HIGH group (p < 0.05 
and average expression > 1) were considered as SOX2 positively correlated genes, while genes with significantly 
higher expression in the LOW group (p < 0.05 and average expression > 1) were considered as SOX2 negatively 
correlated genes. The expression was measured in RPKM and quantile normalized. Results represent the 
mean ± S.E.M. *indicates p < 0.05, **indicates p < 0.01, and ***indicates p < 0.001.
www.nature.com/scientificreports/
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In the next experiment, we sought to determine whether the increased expression of CDKN1A by SOX2 
siRNA alters the cell cycle. As shown in Fig. 4, SOX2 siRNA induced the G1 cell cycle arrest in lung SCC (EBC2 
and LK2) cells, presumably through the induced expression of CDKN1A. Inhibition of CDKN1A by siRNAs did 
not influence the cell cycle in EBC2 and LK2 cells (Fig. 4) presumably because they do not express endogenous 
CDKN1A (Fig. 2A). siRNAs targeting CDKN1A were validated using cells expressing endogenous CDKN1A 
(Supplemental Figure 5). We then investigated whether the G1 arrest induced by the SOX2 siRNA is mediated 
by the increased expression of CDKN1A using the siRNAs targeting CDKN1A. When both SOX2 siRNA and 
CDKN1A siRNA were transfected in EBC2 and LK2 cells, the G1 arrest induced by SOX2 siRNA was restored to 
base level by the presence of the CDKN1A siRNA (Fig. 4), indicating that SOX2 sustains cell cycle by inhibiting 
the expression of CDKN1A, a G1 cell cycle inhibitor.
Discussion
SOX2 has been recognized as a lineage-specific oncogenic transcription factor in lung SCC cells; however, con-
sensus downstream genes of SOX2 have not been established yet. In the present study, we bioinformatically iden-
tified highly consensus downstream genes regulated by SOX2 in lung SCC cells by combining previously-reported 
SOX2 downstream/correlated genes in multiple cancer cell lines with two RNA-seq datasets from 178 lung SCC 
specimens and 105 NSCLC cell lines. We further biologically validated CDKN1A, VIM and ZEB1 as intrinsic 
SOX2 downstream genes in lung SCC cells by loss-of-function and gain-of-function biological experiments.
Unlike SOX2, downstream gene targets of NKX2-1 (also known as TTF-1), another lineage-specific onco-
genic transcription factor in lung AC, are well known. Due to a lung defect in Nkx2-1 knockout mice22, NKX2-1 
has been implicated in the regulation of lung specific genes, including surfactant protein genes23. Recent in vitro 
and in vivo studies using heterozygous or conditionally deleted Nkx2-1 mice also indicate that NKX2-1 directly 
suppresses the expression of mucous genes in asthma and lung cancer24–27. Since Sox2 knockout mice die in early 
embryonic development28, the role of SOX2 in lung had not been understood until recently. Conditional deletion 
of SOX2 in lung epithelium in mice recently revealed that SOX2 is required for proliferation/differentiation of 
airway epithelial cells29,30. In addition to the mouse data, the amplification of SOX2 in human lung SCC31,32 clearly 
indicates that SOX2 regulates genes involved in normal lung morphogenesis and lung SCC. Since SOX2 controls 
tumorigenesis in multiple cancers in addition to lung SCC, multiple groups have reported SOX2 downstream 
genes that are involved in tumor growth in different cancer types. However, such analyses are often based on a 
limited number of cancer cell lines, thus the proposed SOX2 targets are not regulated by SOX2 in other cell lines 
that are not included in the analyses. In order to obtain highly conserved SOX2 downstream targets instead, we 
decided to investigate gene expression profiles of a large number of lung SCC specimens combined with NSCLC 
cell lines, which would identify genes positively/negatively correlated with SOX2 universally in lung SCC cells. 
The RNA-seq data of the 105 NSCLC cell lines, including 4 lung SCC cell lines, were obtained from 675 human 
cancer cell lines, including non-NSCLC cell lines, reported by Klijn et al.15. Ideally, gene expression profiles of 
only lung SCC cell lines should be employed; however, due to the limited number of definitively classified lung 
SCC cell lines (4 cell lines), we include the entire 105 NSCLC cell lines, including not definitively classified cell 
lines such as “lung carcinoma” and “non-small cell lung carcinoma”, for the analysis. However, in the 4 lung 
SCC cell lines, the mean expression of CDKN1A (expression = 27.610) in SOX2-LOW group (LOU-NH91 and 
SK-MES-1) was higher than the mean expression of CDKN1A (expression = 5.787) in the SOX2-HIGH group 
(NCI-H2170 and NCI-H520), indicating that SOX2 is inversely related with CDKN1A even in this limited num-
ber of lung SCC cell lines. The results were further biologically validated using multiple lung SCC cell lines, sug-
gesting that our approach using gene expression profiles of the 105 NSCLC cell lines provide statistical power to 
identify potential genes correlated with SOX2. In addition to determining SOX2 downstream genes in lung SCC 
cell, our approach will be useful for identifying genes regulated by SOX2 in other cancer cells or genes regulated 
by any other transcription factors in multiple cancer cells.
In addition to CDKN1A, BMP2, SNAI1 and VIM were also negatively correlated with SOX2 in our data analysis. 
VIM and SNAI1 are known to induce Epithelial-Mesenchymal Transition (EMT). The EMT is understood as a 
process that induces tumor invasion and metastasis33,34. The loss-of-function study showed that SOX2 inhibited 
VIM and another EMT-related factor ZEB1 in vitro. These results suggest a dual-role of SOX2, in which SOX2 
suppresses lung SCC invasion and metastasis (tumor suppressor) while SOX2 also promotes lung SCC prolifer-
ation (oncogene). Further investigation in vitro and in vivo is required to elucidate this dual function of SOX2 in 
lung SCC tumorigenesis. TNFSF10 (also known as TRAIL) that was negatively correlated with SOX2 in the 105 
NSCLC cell lines (Fig. 2) but not in the 178 lung SCC specimens is known to induce apoptosis; however, SOX2 
siRNA did not induce apoptosis in the lung SCC cell lines that we investigated (Supplemental Figure 6), suggest-
ing that TNFSF10 may be a SOX2 downstream gene in non-lung SCC cells. These results indicate that combining 
multiple RNA-seq datasets with biological experiments is useful to identify unbiased transcriptional downstream 
targets and their associated biological functions.
Among the genes whose expression that we identified as positively correlated with SOX2 (BMP7, CHAC1, 
DHX9, GPX2, MARK1, MSH6, PRKX, RMND5A, SIAH2, TMPRSS4 and USP39) in our bioinformatical analysis 
using both the 178 lung SCC specimens and 105 NSCLC cell lines, all of them were originally reported as top 50 
genes that are positively correlated with SOX2 in stage I/II lung SCC11, indicating that our approach is valid and 
useful to identify gene correlation and potential downstream targets in lung SCC cells. Further biological analysis 
is required to determine whether the above 11 genes are functionally relevant to SOX2 in lung SCC cells.
Our and others’ data clearly indicate that inhibition of SOX2 suppresses lung SCC growth in vitro and in vivo. 
However, our present data indicate that the suppression of lung SCC growth by SOX2 inhibition is mediated by 
cell cycle arrest (via CDKN1A induction) but not apoptotic cell death, suggesting that inhibition of SOX2 may not 
eliminate lung SCC. In addition, SOX2 inhibition slows lung SCC growth and may therefore lead to tumor resist-
ance to chemotherapy that targets rapidly dividing cells. Furthermore, SOX2 inhibition induced genes related to 
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Figure 3. SOX2 suppresses CDKN1A in human lung SCC cells. (A) Immunoblot analysis of SOX2, 
CDKN1A, CDKN1B and TP53 in the indicated lung SCC cell lines. The expression level of β-actin is shown as 
a control. (B) qPCR demonstrated that CDKN1A mRNA was significantly increased after SOX2 silencing by 
SOX2 siRNAs (siSOX2 #1 and siSOX2 #2) in EBC2, LK2 and H520 lung SCC cells. Non-targeting siRNA was 
used as a control (siCtrl). Detection of GAPDH was used for normalization. Results represent the mean ± SD 
(n = 3). Statistical significance was defined as p < 0.01 (*). (C) Immunoblot analysis shows increased CDKN1A 
expression 48 hours after SOX2 siRNAs (siSOX2 #1 and siSOX2 #2) transfection in EBC2, LK2 and H520 lung 
SCC cells. TP53 expression was not changed after SOX2 siRNAs transfection. Non-targeting siRNA was used 
as control (siCtrl). (D) The qPCR analysis showed that CDKN1A mRNA expression was decreased 48 hours 
after Ad-CMV/SOX2 (Ad-SOX2) infection at a MOI of 100 in EBC1 and at a MOI of 10 in H226 lung SCC cells. 
Ad-CMV/Luc (Ad-Luc) did not change CDKN1A mRNA expression in both lung SCC cell lines. Non-treated 
cells were used as a control (Ctrl). Immunoblot analysis demonstrated that CDKN1A protein was suppressed 
48 hours after Ad-SOX2 infection in EBC1 and H226 lung SCC cells. Ad-Luc did not change CDKN1A protein 
expression in the cells. TP53 expression was not changed in the cells. Statistical significance was defined as 
p < 0.01 (*).
www.nature.com/scientificreports/
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EMT, which may cause tumor invasion and metastasis. Thus, targeting of SOX2 as a therapy for lung SCC should 
be taken cautiously. So far, SOX2 has been reported as a better prognosis marker for lung SCC by three groups 
and a worse prognosis marker by one group8,35–38. Identification of therapeutic targets to induce cell death and/or 
inhibit EMT in addition to targeting SOX2 may be required to eradicate SOX2-expressing lung SCC.
In summary, we bioinformatically combined previous reports on SOX2 gene regulation in multiple cancer 
cells with two gene expression datasets from 178 lung SCC specimens and 105 NSCLC cell lines and identified 
SOX2 downstream genes, one of which influences cell growth of multiple lung SCC cells. Further bioinformatical 
approaches, non-biased by previous reports, will make it possible to identify additional SOX2 downstream tar-
gets, which will lead to full understanding of the mechanisms of growth of lung SCC that harbors SOX2 amplifi-
cation and/or highly expressed SOX2 and identify potential therapeutic molecular targets to eradicate lung SCC.
Figure 4. CDKN1A siRNAs released G1 cell cycle arrest induced by SOX2 siRNA. Flow cytometry cell 
cycle analysis of EBC2 and LK2 lung SCC cells transiently transfected with non-targeting siRNA (siCtrl), 
SOX2 siRNA (siSOX2), CDKN1A siRNA (siCDKN1A) or the mixture of SOX2 and CDKN1A siRNAs 
(siSOX2 + siCDKN1A). Cells were harvested at 72 hours after siRNA transfection. Indicated in the inset of 
each panel are the percentages of each phase of cell cycle, where values represent the mean ± SD of triplicate 
measurements.
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Materials and Methods
Bioinformatical determination of SOX2 positively or negatively correlated genes in the TCGA 
human lung squamous cell carcinoma (SCC) samples. The RNA-seq data of human lung squamous 
cell carcinoma (n = 178) were downloaded from The Cancer Genome Atlas (TCGA) data portal https://tcga-
data.nci.nih.gov/docs/publications/lusc_2012/gaf.gene.rpkm.20111213.csv.zip. Expression values were meas-
ured in RPKM. For details on the original processing of the data, refer to the Supplemental Information of the 
original paper14. Expression values were quantile normalized using the “normalize.quantiles” function in the 
Bioconductor package preprocessCore (http://www.bioconductor.org/packages/release/bioc/html/preprocess-
Core.html). We divided the 178 samples into two groups based on their SOX2 expression values; the SOX2-HIGH 
group contained 89 lung SCC samples with their SOX2 expression greater than the median in the 178 samples 
(expression > 55.594); and the remaining 89 lung SCC samples comprised the SOX2-LOW group. Two-tailed 
Welch’s t-test was used to determine the significance of gene expression between the two groups. Genes with 
significantly higher expression in SOX2-HIGH group (p < 0.05 and average expression > 1) were considered as 
SOX2 positively correlated genes, while genes with significantly higher expression in SOX2-LOW group (p < 0.05 
and average expression > 1) were considered as SOX2 negatively correlated genes.
Bioinformatical determination of SOX2 positively or negatively correlated genes in the human 
non-small cell lung cancer (NSCLC) cell lines. The RNA-seq data of human cancer cell lines (n = 675) 
were downloaded from ArrayExpress using accession code E-MTAB-2706 (https://www.ebi.ac.uk/arrayexpress/
experiments/E-MTAB-2706). 105 out of 675 samples were selected as non-small cell lung cancer (NSCLC) cell 
lines for analysis based on the following sample annotations; “OrganismPart” is lung and “Disease” is lung car-
cinoma, lung adenocarcinoma, lung anaplastic carcinoma, non-small cell lung carcinoma, squamous cell lung 
carcinoma, large cell lung carcinoma, lung mucoepidermoid carcinoma, lung papillary adenocarcinoma, lung 
adenosquamous carcinoma, bronchoalveolar adenocarcinoma, or squamous cell carcinoma. Among the 105 
NSCLC cell lines, four were lung SCC cell line, including SK-MES-1, NCI-H520, NCI-H2170 and LOU-NH91. 
Expression values were measured in RPKM. For details on the original processing of the data, refer to the orig-
inal paper15. The expression values were quantile normalized using the “normalize.quantiles” function in the 
Bioconductor package preprocessCore. We divided the 105 NSCLC cell lines into two groups based on their 
SOX2 expression; SOX2-HIGH group contained 20 NSCLC cell lines with their SOX2 expression greater than 
the mean in the 105 NSCLC cell lines (expression > 12.195; e.g., NCI-H2170 and NCI-H520 lung SCC cell lines); 
and the remaining 85 NSCLC cell lines comprised SOX2-LOW group (e.g., LOU-NH91 and SK-MES-1 lung 
SCC cell lines). Two-tailed Welch’s t-test was used to determine the significance of gene expression between the 
two groups. Genes with significantly higher expression in SOX2-HIGH group (p < 0.05 and average expression 
> 1) were considered as SOX2 positively correlated genes, while genes with significantly higher expression in 
SOX2-LOW group (p < 0.05 and average expression > 1) were considered as SOX2 negatively correlated genes.
Cell Lines and Culture Conditions. The human lung SCC cells H520, H226, the human lung carcinoma 
cells A549 and human foreskin fibroblast HFF1 were obtained from the American Type Culture Collection 
(Manassas, VA) and grown in RPMI 1640 (H520 and H226) or high glucose Dulbecco’s modified Eagle medium 
(A549 and HFF1) supplemented with 10% heat-inactivated fetal bovine serum. The lung SCC cells EBC1, 
EBC2, SQ5, LK2 were kindly provided by Dr. Kiura Katsuyuki (Department of Respiratory medicine, Okayama 
University Graduate School of Medicine and Dentistry, Okayama, Japan) and grown in RPMI 1640 supplemented 
with 10% heat-inactivated fetal bovine serum. All cell lines were cultured in 10% CO2 at 37 °C.
Immunohistochemistry. Sections were sequentially deparaffinized through a series of xylene, graded etha-
nol, and water immersion steps. After being autoclaved in target retrieval solution (Dako, Carpinteria, CA, USA) 
for 15 minutes, sections were incubated with 3% hydrogen peroxide for 5 minutes to block endogenous perox-
idase activity. A primary antibody specific for human SOX2 and CDKN1A was obtained from Cell Signaling 
Technology (Beverly, MA). Specimens were incubated overnight at 4 °C with a 1:50 dilution of SOX2 or CDKN1A 
antibody followed by three washes with TBS. The slides were treated with streptavidin-biotin complex (Envision 
System labeled polymer, horseradish peroxidase [HRP], Dako, Carpinteria, CA) for 60 minutes at room tem-
perature. Immunoreactions were visualized using a 3,3′ -diaminobenzidine (DAB) substrate-chromogen solu-
tion (Dako Cytomation Liquid DAB Substrate Chromogen System, Dako) and counterstained with hematoxylin. 
Sections were immersed in an ethanol and xylene bath and mounted for examination. For immunohistochemis-
try analysis, 40 lung SCC tissue sections were obtained from patients diagnosed with lung SCC who underwent 
surgical resection at Kawasaki Hospital, Okayama, Japan. The experimental protocol was approved by the Ethics 
Review Committee of Kawasaki Medical School (Ethics Committee reference number: 1310) and all experi-
ments were performed in accordance with relevant guidelines and regulations of Kawasaki Medical School. The 
informed consent was obtained from all subjects.
siRNA mediated inhibition of SOX2 and CDKN1A. Cells were plated in a 6-well plate at a density of 
3 × 105 per well and cultured overnight at 37 °C. The following day 100 pmol of the different SOX2 siRNA (#1: 
D-011778-01, #2: D-011778-02), CDKN1A siRNA (#1: D-003471-01, #2: 003471-02) or nontargeting siRNA 
(siCtrl; Thermo Scientific) were transfected using 7.5 μ l of Lipofectamine RNAi MAX reagent (Invitrogen, Life 
Technologies, Carlsbad, CA) according to the manufacturer’s instructions. Incubation time for transfection rea-
gents was 24 hours, at which time the medium was replaced with fresh regular medium. Cells were harvested 
48 hours after transfection for immunoblotting or colony formation assays.
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Adenoviral vectors. The recombinant adenoviral vector Ad-CMV/SOX2 (Ad-SOX2) was obtained from 
VECTOR BioLabs (Malvern, PA) and the optimal multiplicity of infection (MOI) was determined by infecting 
each cell line with Ad-CMV/GFP and assessing the expression of GFP. The experimental protocol was approved 
by the institutional biosafety committee of Kawasaki Medical School (Reference number: 14-07) and carried out 
in accordance with the approved guidelines.
Cell viability assay. Cells were plated in 12-well plates at a density of 1 × 105 cells and cultured overnight at 
37 °C. The following day 100 pmol of two different SOX2 siRNA described above was transfected using 3.25 μ l of 
Lipofectamine RNAi MAX reagent (Invitrogen, Life Technologies) according to the manufacturer’s instructions. 
Cells were harvested 48 hours after transfection and viable cells were assessed by a TC20 automated cell counter 
(Bio-Rad, Hercules, CA)39.
Colony formation assay. Cells were plated in a 6-well plate at a density of 2 to 3 × 105 per well and cultured 
overnight at 37 °C. The following day 100 pmol of different kinds of SOX2 siRNA described above were transfected 
using 7.5 μ l of Lipofectamine RNAi Max reagent (Invitrogen, Life Technologies, Carlsbad, CA) according to the 
manufacturer’s instructions. Incubation time for transfection reagents was 24 hours, at which time the medium 
was replaced with fresh regular medium. Cells were harvested 48 hours after transfection, counted, plated in trip-
licate at a density of 5 × 102 cells in 6-well plates for 14 days. The cells were then stained with Diff-Quik (Sysmex, 
Kobe, Japan)40. Colonies (a group of aggregated cells numbering at least 50) were then counted. The mean number 
of the control group was arbitrarily set to 100%, and all other numbers were normalized and percentage-specific 
cytotoxicity compared to colony formation in the control group was calculated.
Immunoblot analysis. Cells were lysed in ice-cold M-PER lysis buffer purchased from Thermo Fisher 
Scientific (Rockford, IL). Cell lysates were clarified by centrifugation (20 min at 15,000 × g at 4 °C) and protein 
concentration determined using the BCA protein assay (Thermo Fisher Scientific). Equal amounts of protein 
were separated on an SDS-PAGE gel. The gel was electrophoretically transferred to a Hybond PVDF transfer 
membrane (GE. Healthcare Ltd., Piscataway, NJ) and incubated with primary and secondary antibodies accord-
ing to the Supersignal® West Pico chemiluminescence protocol (Pierce, Rockford, IL). Antibody specific for 
β-actin was obtained from Sigma (St. Louis, MO) and antibody specific for SOX2, CDKN1A, CDKN1B, CDH1 
and VIM were obtained from Cell Signaling Technology (Beverly, MA). Antibody specific for ZEB1 and TP53 
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Secondary horseradish peroxidase-conjugated 
antibodies were obtained from Jackson Immunoresearch Laboratories (West Grove, PA).
Real time PCR. Total RNA from the cultured cells was obtained using TRIzol (Invitrogen, Life Technologies, 
Carlsbad, CA). Two μ g of total RNA was used for reverse transcription. Reverse transcription was per-
formed at 37 °C for 15 min using PrimeScript RT reagent Kit (Takara Bio, Inc., Shiga, Japan). Specific probes 
for SOX2 (Hs01053049_s1), CDKN1A (Hs00355782_m1) and Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (Hs03929097_g1) for TaqMan Gene Expression Assays were obtained from Applied Biosystems (Life 
Technologies, CA). The real-time PCR reactions were carried out in a 48-well microtiter plate using the TaqMan 
Gene Expression Master Mix (Applied Biosystems). The reaction was performed in triplicate for each sample. 
The fluorescence of the PCR products was detected by TaqMan One-Step RT-PCR. The number of cycles for 
the amplification plot to reach the threshold limit (Ct value) was used for quantification. GAPDH was used as 
endogenous control.
Flow cytometric analysis for cell cycle and apoptosis. For cell cycle analysis, cells were plated in 
6-well plates at a density of 2 × 105 cells per well and cultured overnight at 37 °C. The following day 100 pmol 
of SOX2 siRNA #1 and/or CDKN1A siRNA #1 was transfected using 7.5 μl of Lipofectamine RNAi Max reagent 
(Invitrogen, Life Technologies, Carlsbad, CA) according to the manufacturer’s instructions. Nontargeting siRNA 
(siCtrl) was used as a control. 48 hours after transfection, cells were harvested and washed once with PBS. Cells 
were resuspended in PBS containing 0.2% Triton X-100 and 1 mg/ml RNase for 5 min at room temperature and 
then stained with propidium iodide at 50 μ g/ml to determine DNA cell cycle using a FACS Verse (BD Bioscience, 
San Jose, CA). Doublets, cell debris, and fixation artifacts were gated out, and DNA cell cycle was determined 
using FACSuite Version 1.0.2.2238. To detect apoptosis, 100 pmol of SOX2 siRNA #1 or #2 was transfected. 
Cells were analyzed by flow cytometry 48 hours after transfection staining with AnnexinV-FITC conjugate (BD 
Bioscience) and propidium iodide according to manufacturer’s protocol. Non-targeting siRNA (siCtrl) was used 
as control.
Mouse experiments. LK2 or EBC2 lung squamous carcinoma cells were plated in 10 cm dishes at a density 
of 4 × 106 per dish and cultured overnight at 37 °C. The following day 580 pmol of the two different SOX2 siRNA 
described above or nontargeting siRNA (siCtrl; Thermo Scientific) was transfected using 43 μ l of Lipofectamine 
RNAi Max reagent (Invitrogen, Life Technologies, Carlsbad, CA) according to the manufacturer’s instructions. 
Incubation time for transfection reagents was 24 hours, at which time medium was replaced with fresh regular 
medium. Cells were harvested and washed once with PBS and then resuspended in culture medium. Human lung 
cancer xenografts were established in 6-wk-old female BALB/c nude mice (Charles River Laboratories Japan, 
Kanagawa, Japan) by subcutaneous (s.c.) inoculation of siRNA (SOX2 #1, SOX2 #2 or non-targeting) transfected 
LK2 or EBC2 lung SCC cells (2 × 106 cells/200 μ l) into the right dorsal flank. Tumors were measured two times 
a week, and tumor volume was calculated as a x b2 × 0.5, where a and b were large and small diameters, respec-
tively. The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of 
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Kawasaki Medical School (Ethics Committee reference number: 14-005) and carried out in accordance with the 
approved guidelines.
Statistical analysis. Statistically significant differences between means and medians of the study groups 
were evaluated using Student’s t-test except for Figs 1 and 2. Statistical significance was defined as p < 0.01 (*).
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